Press Releases

CIRCASSIA GROUP PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019

  Oxford, UK – 16 June 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR) today announces its preliminary results for the year ended 31 December 2019 and a post-period update.   Financial progress...

View details

Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest

The information contained within this announcement is deemed by Circassia Pharmaceuticals plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory...

View details

Circassia Announces Business Update

Click here to download the full press release Oxford, UK – 9 January 2020: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces a business...

View details

Update on Circassia’s Licensing Agreement with BeyondAir Inc. for LungFit PH

Click here to download the full press release Oxford, UK – 19 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, provides an update on...

View details

Circassia Announces Board Changes

Click here to download the full press release Oxford, UK – 5 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces a number...

View details

Circassia Announces Duaklir® US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019

Click here to download the full press release – Duaklir® launch expands Circassia’s US portfolio of COPD products alongside Tudorza® – Oxford, UK and Morrisville, NC, United States – 21 October 2019: Circassia Pharmaceuticals plc...

View details

Interim results for the six months ended 30 June 2019

Click here to download the full 2019 interim results Oxford, UK – 26 September 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its...

View details

Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer

Click here to download the full press release – COO to join Board and SVP R&D to step down as Director reflecting Company’s commercial focus – Oxford, UK – 12 August 2019: Circassia Pharmaceuticals plc...

View details

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Click here to download full press release Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication...

View details

Preliminary Results for the Year Ended 31 December 2018

Click here to download the full 2018 preliminary results statement Oxford, UK – 1 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces...

View details